FindTrial
Sign In

PF-07081532

DRUG9 trials

Sponsors

Pfizer

Conditions

Diabetes MellitusDiabetes Mellitus Type 2HealthyHealthy VolunteersHepatic ImpairmentObesityRenal ImpairmentType 2 Diabetes

Phase 1

Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants
CompletedNCT04148209
PfizerHealthy
Start: 2019-11-05End: 2020-03-17Updated: 2020-03-25
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
CompletedNCT04305587
PfizerDiabetes Mellitus Type 2
Start: 2020-03-16End: 2021-07-14Updated: 2024-02-05
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
CompletedNCT05158244
PfizerType 2 Diabetes Mellitus
Start: 2021-12-22End: 2022-06-15Updated: 2024-08-12
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
CompletedNCT05478603
PfizerHealthy Volunteers, Hepatic Impairment
Start: 2022-08-01End: 2023-04-05Updated: 2024-08-22
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
TerminatedNCT05510245
PfizerRenal Impairment, Type 2 Diabetes
Start: 2022-08-29End: 2023-07-20Updated: 2024-11-05
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
TerminatedNCT05671653
PfizerObesity
Start: 2023-01-19End: 2023-11-03Updated: 2025-01-14
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
CompletedNCT05745701
PfizerHealthy
Start: 2023-02-22End: 2023-05-29Updated: 2024-09-23
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
TerminatedNCT05788328
PfizerHealthy
Start: 2023-03-27End: 2023-09-11Updated: 2024-11-15

Phase 2

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
TerminatedNCT05579977
PfizerDiabetes Mellitus, Obesity
Start: 2022-10-27End: 2023-09-22Updated: 2024-08-01

Related Papers

Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
PubMed2026-05-01
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
Diabetes Obesity and Metabolism2024-10-1617 citations
Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
Diabetes Obesity and Metabolism2024-05-1612 citations